Cargando…

Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study

In patients with metastatic renal cell carcinoma response rates of 7–26% have been achieved with immunotherapy. A high response rate of 48% in 35 patients has been reported for treatment with the combination of interferon-α (IFN-α), interleukin-2 (IL-2) and 5-fluorouracil (5-FU) (Atzpodien et al (19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herpen, C M L van, Jansen, R L H, Kruit, W H J, Hoekman, K, Groenewegen, G, Osanto, S, Mulder, P H M De
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374413/ https://www.ncbi.nlm.nih.gov/pubmed/10732744 http://dx.doi.org/10.1054/bjoc.1999.0997

Ejemplares similares

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study
por: Allen, M J, et al.
Publicado: (2000)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995)

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
por: Punt, C. J., et al.
Publicado: (1997)

Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer
Publicado: (2001)

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
por: Hauschild, A, et al.
Publicado: (2001)

Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion
por: Nio, Y, et al.
Publicado: (1999)

Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?
por: Li, Ying, et al.
Publicado: (2023)

A randomized phase II trial of 5-fluorouracil, with or without human interferon-β, for advanced colorectal cancer
por: Villar-Grimalt, A, et al.
Publicado: (1999)

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.
por: Stouthard, J. M., et al.
Publicado: (1996)

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
por: Braybrooke, J P, et al.
Publicado: (2000)

Does nivolumab combined with fluorouracil-based chemotherapy produce higher objective response rate than other immunochemotherapy regimes in metastatic esophageal cancer?: authors reply
por: Gao, Zhen, et al.
Publicado: (2023)

Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study
por: Hong, R L, et al.
Publicado: (1999)

Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
por: Yeh, K-H, et al.
Publicado: (2000)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
por: Goey, S. H., et al.
Publicado: (1996)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
por: Chau, I, et al.
Publicado: (2001)

MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
por: Cascinu, S., et al.
Publicado: (1994)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Bifidobacterium in anticancer immunochemotherapy: friend or foe?
por: Procaccianti, Giorgia, et al.
Publicado: (2023)

The α Chemokine, Interleukin 8, Inhibits the Antiviral Action of Interferon α
por: Khabar, Khalid S.A., et al.
Publicado: (1997)

The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma
por: Saito, H, et al.
Publicado: (1999)

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression
por: Ota, H, et al.
Publicado: (2005)

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001)

Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-α
por: Hung, W-C, et al.
Publicado: (1999)

Direct activation of oestrogen receptor- α by interleukin-6 in primary cultures of breast cancer epithelial cells
por: Speirs, V, et al.
Publicado: (2000)

Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast
por: Harper-Wynne, C, et al.
Publicado: (1999)

Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-α and retinoids
por: Brodowicz, T, et al.
Publicado: (1999)

Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion
por: Kanai, T, et al.
Publicado: (2000)

Low interleukin-1α messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma
por: Seddighzadeh, M, et al.
Publicado: (2001)

Identification of the Genes Chemosensitizing Hepatocellular Carcinoma Cells to Interferon-α/5-Fluorouracil and Their Clinical Significance
por: Sakabe, Tomohiko, et al.
Publicado: (2013)

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
por: Iacopetta, B, et al.
Publicado: (2001)

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial
por: Ravaud, A, et al.
Publicado: (2003)

Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
por: Schmidt-Wolf, I G H, et al.
Publicado: (1999)

Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma
por: Noda, T, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_m6a2ie50f5k65bogeu3kuqk6jj